Metropolis Healthcare Ltd

Metropolis Healthcare Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The window will be shut from June 30, 2026, until 48 hours after the declaration of the financial results for the quarter ending June 30, 2026. The company will provide further details regarding the board meeting to declare these results in due course.

Metropolis Healthcare Ltd. has revised its consolidated financial results for the quarter and financial year ended March 31, 2026, due to an inadvertent error in the 'Profit attributable to owners of the Company' figure for the quarter ended March 31, 2025. The company has also released standalone financial results for the same period. The correction is administrative, does not impact the current financial year, and is not considered material. Revised results are enclosed with the filing.

Metropolis Healthcare Ltd reported a strong Q4FY26 performance with a 23% YoY increase in revenue to ₹425 Cr. EBITDA rose by 71% YoY to ₹108 Cr, and PAT increased by 75% YoY to ₹51 Cr. Patient volumes grew 11% YoY, and test volumes increased 14% YoY. The Board has approved a dividend of ₹1 per share. B2C revenues grew 20% YoY, while B2B revenues increased 28% YoY. TruHealth and Specialty portfolios grew 24% YoY and 31% YoY, respectively.

Metropolis Healthcare Ltd announced the transition of Dr. Nilesh Shah from his full-time role as President - Internal Assurance to an advisory role, effective May 14, 2026. Consequently, Dr. Shah will no longer be classified as Senior Management Personnel from the close of business hours on May 13, 2026. The board also approved the audited standalone and consolidated financial results for the year ended March 31, 2026, declared a second interim dividend of ₹1 per equity share, and recommended the appointment of Deloitte Haskins & Sells as statutory auditors.

Metropolis Healthcare Ltd. announced its audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board approved the results and declared a 2nd interim dividend of ₹1 per equity share. They also approved the appointment of Deloitte Haskins & Sells as Statutory Auditors, replacing B S R & Co. LLP. Dr. Nilesh Shah transitioned from his full-time role to an advisory role.

Metropolis Healthcare Ltd's board approved a 2nd interim dividend of ₹1 per equity share (face value ₹2) for FY2025-26, with a record date of May 19, 2026. The board also approved the audited standalone and consolidated financial results for the year ended March 31, 2026. Additionally, they recommended the appointment of Deloitte Haskins & Sells as statutory auditors, replacing B S R & Co. LLP, and noted the transition of Dr. Nilesh Shah to an advisory role.

Metropolis Healthcare Ltd's board approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. They declared a 2nd interim dividend of ₹1 per equity share with a record date of May 19, 2026. Deloitte Haskins & Sells LLP was recommended as the new statutory auditor, replacing B S R & Co. LLP. Dr. Nilesh Shah transitioned from President - Internal Assurance to an advisory role, ceasing to be Senior Management Personnel.

Metropolis Healthcare Ltd's Nomination and Remuneration Committee approved the allotment of 4,200 equity shares under the MHL-RSU Plan 2020 at an exercise price of ₹2 each. It also granted stock benefits, including 14,236 units under the Metropolis – Restrictive Stock Units Plan, 2025 and 2,12,345 options under the Metropolis – Employees Stock Options Plan, 2025. 50% of the allotted equity shares are subject to a 1-year lock-in period.

Metropolis Healthcare Ltd has announced a meeting of its Board of Directors on May 13, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board will also consider the declaration of a second interim dividend, if any, on the company's equity shares for the financial year 2025-26. The trading window for dealing in the company's securities has been closed from April 1, 2026, to May 15, 2026.

Metropolis Healthcare Ltd. has provided a business update for Q4FY26, highlighting a ~23% Y-o-Y growth in consolidated revenues. This growth was primarily driven by the TruHealth wellness segment and specialized testing segment. The B2B and B2C channels also showed robust growth. Acquisitions from the previous year are progressing well, with integration efforts now translating into positive outcomes. The MHL Organic segment saw a ~14.5% Y-o-Y growth in revenue, and EBITDA margins improved due to operating leverage and efficiency gains. The financial results are subject to audit.